Celularity Inc
CELU1.300USD
+0.130+11.11%
終値 02/06, 16:00（ET）15分遅れの株価
36.68M時価総額
損失額直近12ヶ月PER
詳細情報 Celularity Inc 企業名
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Celularity Incの企業情報
企業コードCELU
会社名Celularity Inc
上場日May 23, 2019
最高経営責任者「CEO」Hariri (Robert J)
従業員数123
証券種類Ordinary Share
決算期末May 23
本社所在地170 Park Ave
都市FLORHAM PARK
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号07932
電話番号19087682170
ウェブサイトhttps://celularity.com/
企業コードCELU
上場日May 23, 2019
最高経営責任者「CEO」Hariri (Robert J)
Celularity Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+3281.00%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+28847.00%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+3281.00%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+28847.00%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sat, Jan 3
更新時刻: Sat, Jan 3
株主統計
種類
株主統計
株主統計
比率
Genting Bhd
21.97%
Hariri (Robert J)
9.91%
Starr International Company, Inc.
5.30%
Lincoln Alternative Strategies LLC
4.27%
C.V. Starr & Co., Inc.
2.65%
他の
55.90%
株主統計
株主統計
比率
Genting Bhd
21.97%
Hariri (Robert J)
9.91%
Starr International Company, Inc.
5.30%
Lincoln Alternative Strategies LLC
4.27%
C.V. Starr & Co., Inc.
2.65%
他の
55.90%
種類
株主統計
比率
Corporation
26.24%
Individual Investor
15.43%
Investment Advisor
8.72%
Insurance Company
2.65%
Investment Advisor/Hedge Fund
1.30%
Hedge Fund
0.38%
Research Firm
0.17%
Family Office
0.04%
他の
45.07%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
71
3.82M
13.73%
--
2025Q3
80
3.82M
16.36%
+119.97K
2025Q2
92
3.70M
17.46%
+189.07K
2025Q1
120
3.51M
18.18%
-579.52K
2024Q4
135
3.39M
17.70%
+120.20K
2024Q3
149
3.27M
18.60%
+20.75K
2024Q2
160
3.32M
18.56%
+109.90K
2024Q1
166
3.20M
18.29%
-780.71K
2023Q4
164
3.20M
20.76%
-511.70K
2023Q3
164
3.71M
20.21%
+96.25K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Genting Bhd
6.34M
22.25%
--
--
Oct 30, 2025
Hariri (Robert J)
2.86M
10.04%
+3.28K
+0.11%
Oct 30, 2025
Starr International Company, Inc.
1.53M
5.37%
--
--
Oct 30, 2025
Lincoln Alternative Strategies LLC
1.23M
4.32%
+1.23M
--
Jul 14, 2025
C.V. Starr & Co., Inc.
764.07K
2.68%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
676.65K
2.38%
+176.52K
+35.29%
Sep 30, 2025
Ling (Geoffrey M. D.)
472.29K
1.66%
+192.42K
+68.75%
Dec 29, 2025
Diamandis (Peter)
441.18K
1.55%
+192.42K
+77.35%
Dec 29, 2025
Parks (Diane L.)
344.98K
1.21%
+192.42K
+126.12%
Dec 29, 2025
Levien (Vincent)
128.70K
0.45%
+125.00K
+3379.29%
Dec 29, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
比率0%
DFA Dimensional US Sustainability Core 1 ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
日付
配当落ち日
種類
比率
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
